Temple research paves the way for first Phase 1/2 clinical trials of CRISPR-based therapy for HIV
For the last seven years, researchers at the Lewis Katz School of Medicine at Temple University have been developing and […]
» Read morenohealthproblemsnews.com
Home »
For the last seven years, researchers at the Lewis Katz School of Medicine at Temple University have been developing and […] A body mass index (BMI) ≥30 kg/m2, rilpivirine resistance–associated mutations, and the HIV-1 subtype A6/A1 can raise a person’s risk […] Headache was the most common adverse event (AE) people experienced in 72 weeks of taking the once-daily investigational two-drug HIV […] NEW YORK (Reuters Health) – People with HIV have a rate of sudden cardiac death that is more than double […] University of Maryland School of Medicine (UMSOM) researchers have identified the most toxic proteins made by SARS-CoV-2-;the virus that causes […] An antibody infusion being tested for preventing HIV does not seem to thwart most infections—but its success against certain strains […] Immune cells specialize to ensure the most efficient defense against viruses and other pathogens. Researchers at the University of Basel […] Foldamers have specific properties that make them superior to conventional peptides. Foldamers are self-organizing and can form higher order structures. […] Skip to: What are the symptoms of vaginal infection? What are the consequences of vaginal infection? What triggers vaginal infection? […] An investigational anti-HIV antibody delivered intravenously once every eight weeks safely and effectively prevented acquisition of HIV strains sensitive to […]
Temple research paves the way for first Phase 1/2 clinical trials of CRISPR-based therapy for HIV
HIV: Failed viral suppression in CAB/RPV linked to 3 Risk Factors
HIV: Could Another Two-Drug Regimen Be on the Horizon?
Presumed Sudden Cardiac Death Among HIV-Infected Often Not Due to Coronary Artery Disease
FDA-approved cancer drug blunts SARS-CoV-2 protein's detrimental effects
Disappointment and hope from two HIV prevention trials
Researchers shed light on T-cell receptor activation in response to infection
Beta Peptide Foldamers
Common Triggers for Vaginal Infections
Antibody infusions prevent acquisition of some HIV strains, studies find